drugset / Trial / NCT02011841
Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients
RandomizedParallel-groupOpen-labelPrevention
Summary
The aim of this study is to evaluate whether long-term rifaximin administration reduces spontaneous bacterial peritonitis recurrence rate in cirrhotic patients.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ciprofloxacin | Small molecule | 500 mg | Oral |
| Subject | Rifaximin | Other / unclassified | 1200 mg | Oral |